samira shabani; Massoud houshnamnd; tayebeh majidizade; samira sheibania
Volume 26, Issue 1 , 2024
Abstract
A new worldwide pandemic of coronavirus disease 2019 (COVID-19) has resulted in a healthcare crisis with high mortality and morbidity. Presently, several drugs are under accelerated research without established efficacy and are being used to treat COVID-19 patients either as unapproved drug use or as ...
Read More
A new worldwide pandemic of coronavirus disease 2019 (COVID-19) has resulted in a healthcare crisis with high mortality and morbidity. Presently, several drugs are under accelerated research without established efficacy and are being used to treat COVID-19 patients either as unapproved drug use or as clinical trials. To optimally use the drugs, several factors, such as the gene effects, drug interactions, and drug toxicity, should be considered. Genetic polymorphisms are a type of genetic diversity within a populations gene pool that constitute the basis of pharmacokinetics, which causes alteration in the drug function and response. Since there was a limited time to check individual pharmacogenomics markers, it seems population pharmacogenomics tests could be helpful in expecting drug treatment failure in COVID-19 patients. We genotyped and investigated allele frequencies of 33 SNPs located on 10 pharmacogenes from 150 healthy individual samples.A total of 32 potential pharmacogenomics variants relevant to COVID-19 treatment were identified in the Iranian population. Considering them in patients' pharmacotherapy could influence the treatment optimization and reduce severity of adverse effects.
